{"result": "(\"entity\"<|>SOCIEDAD ESPAÑOLA DE ARTERIOSCLEROSIS<|>ORGANIZATION<|>The Sociedad Española de Arteriosclerosis is an organization that provides guidelines for managing dyslipidemia and cardiovascular risk.)\n##\n(\"entity\"<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>ORGANIZATION<|>The European Society of Cardiology is a professional organization that sets guidelines for cardiovascular health and disease management.)\n##\n(\"entity\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>EVENT<|>The Manual de Endocrinología y Nutrición is a reference book that includes guidelines and recommendations for the treatment of dyslipidemia.)\n##\n(\"entity\"<|>CARDONA F<|>PERSON<|>Cardona F is an author of the Manual de Endocrinología y Nutrición, contributing to the guidelines on dyslipidemia management.)\n##\n(\"entity\"<|>ALCAIDE J<|>PERSON<|>Alcaide J is an author of the Manual de Endocrinología y Nutrición, contributing to the guidelines on dyslipidemia management.)\n##\n(\"entity\"<|>FERNÁNDEZ GARCÍA JC<|>PERSON<|>Fernández García JC is an author of the Manual de Endocrinología y Nutrición, contributing to the guidelines on dyslipidemia management.)\n##\n(\"relationship\"<|>SOCIEDAD ESPAÑOLA DE ARTERIOSCLEROSIS<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>Both organizations provide guidelines for managing cardiovascular health and dyslipidemia<|>7)\n##\n(\"relationship\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>SOCIEDAD ESPAÑOLA DE ARTERIOSCLEROSIS<|>The Manual de Endocrinología y Nutrición includes guidelines from the Sociedad Española de Arteriosclerosis<|>8)\n##\n(\"relationship\"<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>EUROPEAN SOCIETY OF CARDIOLOGY<|>The Manual de Endocrinología y Nutrición may reference guidelines from the European Society of Cardiology<|>6)\n##\n(\"relationship\"<|>CARDONA F<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Cardona F is one of the authors of the Manual de Endocrinología y Nutrición<|>9)\n##\n(\"relationship\"<|>ALCAIDE J<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Alcaide J is one of the authors of the Manual de Endocrinología y Nutrición<|>9)\n##\n(\"relationship\"<|>FERNÁNDEZ GARCÍA JC<|>MANUAL DE ENDOCRINOLOGÍA Y NUTRICIÓN<|>Fernández García JC is one of the authors of the Manual de Endocrinología y Nutrición<|>9)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: secundaria (p. ej., diabetes melli-\n         mización debe ser la medida inicial del tratamiento de cualquier dislipidemia. Los factores                                               tus), la experiencia es muy limitada. En el caso de la hiperlipidemia combinada, la adición de\n         dietéticos más claramente implicados en el empeoramiento del perfil lipídico son la ingesta                                               4 g/día de EPA/DHA al tratamiento con estatinas parece conseguir una reducción adicional\n         elevada de grasas saturadas y de colesterol, y el exceso de calorías. El consumo de alcohol                                               de los niveles de triglicéridos, sin que se hayan observado problemas de seguridad graves.\n         influye de forma directa en los niveles de triglicéridos. Existen diversas tablas (en nuestro                                             Referencias:\n         medio la más utilizada es la de la Sociedad Española de Arteriosclerosis) que clasifican los                                              • Amor Fernández AJ, Vinagre Torres I, Perea Castilla V. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española\n         alimentos en tres grupos (recomendables, a limitar o desaconsejables), en función de su                                                     de Endocrinología y Nutrición; 2018. Capítulo 125. Tratamiento de las dislipemias. [citado 11 de noviembre de 2019]. Disponible en:\n                                                                                                                                                     https://manual.seen.es/article?id=5559fe85-9644-42fd-966a-6a43ac18103c\n         conveniencia, en el caso de dislipidemia. Como norma general, la mayor fuente de grasas\n\n\n\n468                                                                                                                                                                                                                                                                         469\n---\n                                                                                                                                                                                                            OBESIDAD,                LÍPIDOS                       8\n                                                                                                                                                                              Y TRASTORNOS ELECTROLÍTICOS\n\n\n\n     39  Según las guías ESC/EAS2016 (European Society of Cardiology/European Society                                               40  En la disbetalipoproteinemia, ¿cuál de las siguientes respuestas es cierta?\n         of Atherosclerosis) para el manejo de la dislipidemia, en el paciente con                                                      A. La prevalencia aproximada es de 1 por cada 1.000 personas.\n         enfermedad renal crónica (señale la respuesta cierta):                                                                         B. Se debe a una mutación heterocigota en el gen de la apoliproteína E.\n         A. Se consideran de riesgo cardiovascular alto (estadio 3) o muy alto (estadio 4-5 o en                                        C. A pesar de las alteraciones lipídicas, clínicamente no se manifiesta con xantomas\n             diálisis).                                                                                                                     tuberosos ni palmares.\n         B. No debe utilizarse combinación de ezetimiba con estatinas, pues no hay estudios en este                                     D.  Existe un defecto en el aclaramiento lipídico de las lipoproteínas, acumulándose los\n             tipo de pacientes.                                                                                                             remanentes de densidad intermedia.\n         C. Se pautarán estatinas de rutina al inicio de la diálisis, independientemente de la\n             existencia de enfermedad cardiovascular.\n         D.  Una vez sometidos a trasplante renal ya no es necesario el uso de estatinas.                                               COMENTARIO\n                                                                                                                                        La disbetalipoproteinemia es un trastorno raro con una frecuencia de una por cada 10.000 per-\n         COMENTARIO                                                                                                                     sonas y fundamentalmente se debe a una homocigosis en la apo E, presentando el genotipo\n                                                                                                                                        apo E2 en homocigosis. Dado que la apo E desempeña un papel crucial en el catabolismo\n         En la tabla 7 figuran las recomendaciones de la ESC/EAS 2016 para el manejo de los lípi-                                       de los quilomicrones y restos de VLDL, estos sujetos afectados presentan elevaciones de\n         dos en pacientes con enfermedad renal crónica moderada-grave con sus correspondientes                                          triglicéridos y colesterol VLDL, además de quilomicrones en ayunas. Pueden presentar xan-\n         niveles de evidencia.                                                                                                          tomas y depósitos de colesterol en los surcos palmares.\n         Tabla 7. Recomendaciones para el manejo de los lípidos en pacientes con enfermedad                                             Referencias:\n                                                                                                                                        • Cardona F, Alcaide J, Fernández García JC. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española\n         renal crónica moderada-grave                                                                                                     de Endocrinología y Nutrición; 2015. Capítulo 124. Epidemiología, diagnóstico y clasificación de las dislipemias;\n                                                                                                                                          [citado 11 de noviembre de 2019]. Disponible en: https://manual.seen.es/article?id=55115050-34cc-451f-99b6-4b97ac18103c\n           RECOMENDACIONES                                                                    CLASE                  NIVEL\n           Los pacientes con ERC estadio 3-5 tienen que considerarse de\n           alto                                                                                   I                      A          41  Respecto a la hiperlipidemia familiar combinada, señale la respuesta falsa:\n           o muy alto\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}